title: Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder.
abstract: Fourteen dogs with histologically-confirmed transitional cell carcinoma (TCC) of the urinary bladder were treated with 300 mg/m2 carboplatin every 3 weeks. Response to therapy was assessed with abdominal radiography, double contrast cystography, urinary bladder ultrasonography and thoracic radiography before therapy and at 6-week intervals during therapy. Dogs were monitored for hematologic toxicity with a CBC and platelet count performed immediately before and 10 to 14 days after carboplatin treatment. Tumor responses included progressive disease in 11 dogs and stable disease in 1 dog. Two dogs were euthanized due to carboplatin toxicity before assessment of tumor response. Toxicity included thrombocytopenia with or without neutropenia in 7 dogs and gastrointestinal toxicity in 6 dogs. Carboplatin therapy was not beneficial in the treatment of TCC in the 14 dogs in this study.
authors.affiliation: Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
authors.forename: R
authors.initials: R
authors.lastname: Chun
authors.forename: D W
authors.initials: DW
authors.lastname: Knapp
authors.forename: W R
authors.initials: WR
authors.lastname: Widmer
authors.forename: D B
authors.initials: DB
authors.lastname: DeNicola
authors.forename: N W
authors.initials: NW
authors.lastname: Glickman
authors.forename: T
authors.initials: T
authors.lastname: Kuczek
authors.forename: A
authors.initials: A
authors.lastname: Degortari
authors.forename: C M
authors.initials: CM
authors.lastname: Han
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D015994:Incidence; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology / Q000662:veterinary; D011860:Radiography, Abdominal / Q000379:methods / Q000662:veterinary; D013902:Radiography, Thoracic / Q000662:veterinary; D013921:Thrombocytopenia / Q000139:chemically induced / Q000453:epidemiology / Q000662:veterinary; D014463:Ultrasonography; D001743:Urinary Bladder / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin